GenSpera Receives Key Patent on Prodrug for Prostate Cancer

GenSpera Receives Key Patent on Prodrug for Prostate Cancer
GenSpera, Inc., a leader in developing prodrug therapeutics for the treatment of cancer, has announced that the United States Patent and Trademark Office (USPTO) issued the patent “Tumor Activated Prodrugs” for GenSpera’s G-202, the company’s lead drug candidate. This patents covers the development of G-202, a prodrug activated by Prostate Specific Antigen (PSA) and designed

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *